Payment overview · 2025
General Payments
$1,324.31
66 reported records · 23 companies
Healthcare provider profile · identity verified
Shilpa Bhatnagar, M. D.
Allopathic & Osteopathic Physicians|Internal Medicine · TEMPE, AZ · NPI 1851385876
Verified facts
What the public records show
CMS Open Payments records show Shilpa Bhatnagar, M. D. received $1,324.31 in general payments during 2025 across 66 reported records.
PFIZER INC. accounted for 11.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Linzess, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $146.56 | 11.1% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $110.78 | 8.4% | 5 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $110.66 | 8.4% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $89.91 | 6.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $79.37 | 6.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $69.49 | 5.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $63.10 | 4.8% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $63.03 | 4.8% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $60.01 | 4.5% | 4 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $59.71 | 4.5% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $55.62 | 4.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.77 | 3.9% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $51.02 | 3.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.01 | 3.6% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $41.51 | 3.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.79 | 2.9% | 2 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $37.63 | 2.8% | 2 | 2025 |
| Saluda Medical Americas, Inc. | Unresolved — no canonical attribution shown | $36.41 | 2.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $28.11 | 2.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.91 | 1.9% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.07 | 1.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.38 | 1.6% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $14.46 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,324.31 | 66 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $139.06 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $110.78 | 5 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $110.66 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $101.60 | 6 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $89.91 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $79.37 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $63.03 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $60.01 | 4 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $59.71 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $55.62 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $53.67 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $53.67 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $51.02 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $49.16 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $41.51 | 2 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $37.63 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $37.63 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $37.63 | 2 | 2025 |
Source payment records
|
|||||
| Evoke Normalized: evoke |
Device | Saluda Medical Americas, Inc. | $36.41 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.54 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.08 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.08 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $28.11 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $27.41 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $7.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 45 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 38 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 139 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 21 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 41 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
73 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
139 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 20 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
45 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 504 | 137 |
| Atorvastatin Calcium | Atorvastatin Calcium | 409 | 131 |
| Levothyroxine Sodium | Levothyroxine Sodium | 396 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 367 | 106 |
| Metformin Hcl | Metformin Hcl | 338 | 96 |
| Lisinopril | Lisinopril | 303 | 94 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 277 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 235 | 80 |
| Fluoxetine Hcl | Fluoxetine Hcl | 204 | 62 |
| Omeprazole | Omeprazole | 190 | 68 |
| Trazodone Hcl | Trazodone Hcl | 176 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 174 | 77 |
| Gabapentin | Gabapentin | 166 | 57 |
| Ozempic | Semaglutide | 139 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 136 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 129 | 72 |
| Simvastatin | Simvastatin | 120 | 42 |
| Azithromycin | Azithromycin | 112 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 32 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 86 | 36 |
| Celecoxib | Celecoxib | 83 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 25 |
| Atenolol | Atenolol | 75 | 24 |
| Cephalexin | Cephalexin | 73 | 54 |
| Mounjaro | Tirzepatide | 73 | 16 |
| Alendronate Sodium | Alendronate Sodium | 71 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 63 | 48 |
| Methylprednisolone | Methylprednisolone | 62 | 51 |
| Fluconazole | Fluconazole | 60 | 23 |
| Famotidine | Famotidine | 57 | 21 |
| Montelukast Sodium | Montelukast Sodium | 56 | 22 |
| Potassium Chloride | Potassium Chloride | 56 | 17 |
| Buspirone Hcl | Buspirone Hcl | 55 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 55 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 17 |
| Allopurinol | Allopurinol | 53 | 19 |
| Bupropion Xl | Bupropion Hcl | 49 | 16 |
| Sertraline Hcl | Sertraline Hcl | 46 | 16 |
| Gemtesa | Vibegron | 45 | 16 |
| Metformin Hcl Er | Metformin Hcl | 45 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 41 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | 11 |
| Xarelto | Rivaroxaban | 41 | 11 |
| Nystatin | Nystatin | 40 | 13 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 39 | 13 |
| Linzess | Linaclotide | 38 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 33 |
| Carvedilol | Carvedilol | 37 | 11 |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 13 |
| Baclofen | Baclofen | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 34 | 14 |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | 11 |
| Meclizine Hcl | Meclizine Hcl | 33 | 19 |
| Prednisone | Prednisone | 33 | 24 |
| Eliquis | Apixaban | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Estradiol | Estradiol | 31 | 18 |
| Furosemide | Furosemide | 30 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 23 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 20 |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | 16 |
| Mirtazapine | Mirtazapine | 20 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Gvoke Hypopen 2-Pack | Glucagon | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Budesonide Er | Budesonide | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Amlodipine-Valsartan-Hctz | Amlodipine/Valsartan/Hcthiazid | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,324.31 · 66 records | PFIZER INC. | AREXVY, Dexcom G6 Transmitter, EVENITY, Evoke, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, GLYCATE, GVOKE HYPOPEN, General - Pain Management, JARDIANCE, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, Kerendia, LINZESS, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PAXLOVID, PROLIA, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error